Socioeconomic Phenotype Index (SPI™): Reframing Social Determinants as Biological Terrain

Executive Summary

The Socioeconomic Phenotype Index (SPI™) represents a paradigm shift in how health science conceptualizes the role of socioeconomic status. For decades, poverty, access barriers, and discrimination have been categorized as “social determinants of health” (SDOH). While this framing acknowledges their impact, it relegates them to the periphery of medical science. SPI™ reframes these determinants as phenotypes, measurable biological terrains that directly influence disease onset, chronicity, flare cycles, and treatment responsiveness. By integrating socioeconomic status into phenotype classification, SPI™ provides researchers, clinicians, and policymakers with a quantifiable tool for stratifying risk, designing trials, and ensuring equity in care delivery.

Background

The field of precision medicine has traditionally focused on biological phenotypes such as genetic mutations, hormonal imbalances, or immune dysregulation. Social determinants, by contrast, are treated as “context” , important, but external to the biological model. However, robust evidence demonstrates that chronic socioeconomic instability produces biological signatures:

• Immune modulation: Chronic stress alters cytokine production and inflammatory pathways.

  
  

• Endocrine disruption: Financial or housing insecurity triggers sustained cortisol elevation and HPA axis dysregulation.

  
  

• Neurological impact: Prolonged exposure to discrimination and trauma rewires neural circuits linked to autonomic regulation.

These are not “external” modifiers but phenotypic drivers. The absence of a structured model has left a gap in both research and clinical practice, one that SPI™ fills.

The SPI™ Model

Traditional models treat poverty, access gaps, and discrimination as “external factors.” SPI™ reframes them as biological terrain modifiers that affect immune response, flare cycles, and remission probability. The system scores patients across three domains, Structural Security, Access to Care, and Psychosocial Buffering, then generates a composite index that stratifies risk and resilience.

Domains

SPI™ is composed of three domains, each scored on a 0–3 scale:

1. Structural Security

   • Housing stability

   • Financial security

   • Food security

   • Educational access

2. Access to Care

   • Insurance coverage

   • Geographic proximity

   • Provider availability

   • Cultural and linguistic competence

3. Psychosocial Buffering

   • Community and family networks

   • Institutional trust

   • Exposure to violence or discrimination

   • Presence of protective social capital

Formula

SPI Score = (Structural Security + Access to Care + Psychosocial Buffering) ÷ 3

Each domain is scored from 0–3, with higher values representing higher socioeconomic burden.

Range:

• 0.0–0.9 = Advantage phenotype

• 1.0–1.9 = Moderate risk phenotype

• 2.0–2.9 = High risk phenotype

• 3.0 = Extreme risk phenotype

Real-World Example with Calculation

A patient with:

• Structural Security = 2 (chronic housing + financial instability)

• Access to Care = 1 (insurance gaps, but some access)

• Psychosocial Buffering = 3 (domestic violence, systemic exclusion)

SPI Score = (2 + 1 + 3) ÷ 3 = 2.0 → High risk phenotype

Implication: This patient is predisposed to more frequent flares, lower treatment responsiveness, and higher hospitalization risk. Interventions must integrate both clinical and socioeconomic stabilization strategies.

Applications

Clinical Trials

SPI™ enables stratification of participants not just by biology but by socioeconomic terrain. This prevents trial failure due to unrecognized socioeconomic phenotypes that alter drug efficacy.

Health Systems & Insurers

SPI™ offers a measurable framework for risk adjustment and reimbursement. High-SPI patients can be flagged for enhanced care coordination, reducing long-term costs.

Policy & Access

By redefining socioeconomic status as phenotype, SPI™ transforms equity into a biological and economic imperative, not an optional consideration. It provides a hard-data foundation for CMS, NIH, and FDA to enforce broadly accessible standards.

Why It Works

• Biological Validity: Chronic socioeconomic stress reshapes immune, endocrine, and neurological function.

  
  

• Quantifiable Action: Converts SDOH into a measurable, reproducible score.

  
  

• Licensing Value: Provides a modular scoring overlay that can be integrated into CYNAERA’s terrain intelligence ecosystem (Pathos™, VitalGuard™, SymCas™, etc.).

  
  

• Scalability: SPI™ can be implemented globally, with regional calibration for cultural and economic variation.

Conclusion

The Socioeconomic Phenotype Index (SPI™) advances equity science into the domain of measurable biology. By treating socioeconomics as a phenotype rather than a peripheral determinant, SPI™ offers a framework that is scientifically valid, operationally practical, and commercially scalable. Incorporated into CYNAERA’s modular systems, SPI™ has the potential to reshape clinical trials, health policy, and patient outcomes, ensuring that the invisible terrain of inequity is finally quantified and addressed.

CYNAERA Frameworks Referenced in This Paper 

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s prevalence correction frameworks. These publications provide deeper context on prevalence reconstruction, diagnostic suppression, population correction, and disease-burden modeling approaches referenced in this analysis.

• Bioadaptive Systems Therapeutics™ (BST): Engineering Remission Through Terrain Logic

• The Science of Remission: Reversing Infection-Associated Chronic Conditions (IACCs)

• The Pathophysiology of Infection-Associated Chronic Conditions (IACCs)

• Global-CCUC™: CYNAERA Tiered Model for Global ME/CFS Prevalence

• Undercounted from Kabul to Kansas: The Hidden Men of IACCs

• CYNAERA’s VitalGuard™ Environmental Flare Risk Engine

• Corrected National Prevalence Estimates for (IACCs)

• Aligned Intelligence Method (AIM™)

• The Pediatric ME/CFS Crisis

  
  

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

​Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including Pathos™, VitalGuard™, CRATE™, SymCas™, TrialSim™, and BRAGS™, are protected under U.S. Provisional Patent Application No. 63/909,951.

Licensing and Integration

CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.

Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.

About the Author 

Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, Board Member at Solve M.E., and collaborator with Selin Lab for t cell research at the University of Massachusetts.

Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.

Through CYNAERA, she develops modular AI platforms, including the IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.

Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.

References

Academic

1. Marmot, M., & Wilkinson, R. G. (Eds.). (2005). Social determinants of health (2nd ed.). Oxford University Press.

2. Braveman, P., & Gottlieb, L. (2014). The social determinants of health: It’s time to consider the causes of the causes. Public Health Reports, 129(1_suppl2), 19–31.

3. McEwen, B. S., & Gianaros, P. J. (2010). Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease. Annals of the New York Academy of Sciences, 1186(1), 190–222.

4. Williams, D. R., Lawrence, J. A., & Davis, B. A. (2019). Racism and health: Evidence and needed research. Annual Review of Public Health, 40, 105–125.

5. Adler, N. E., & Rehkopf, D. H. (2008). U.S. disparities in health: Descriptions, causes, and mechanisms. Annual Review of Public Health, 29, 235–252.

CYNAERA

1. CYNAERA Institute. (2025). Pathos Symptom-Based Scoring Table. CYNAERA White Paper Series.

2. CYNAERA Institute. (2025). VitalGuard™: Predictive Flare Intelligence from Environmental Terrain. CYNAERA White Paper Series.

3. CYNAERA Institute. (2025). BRAGS™: Bias Research Accountability Grading System. CYNAERA Equity Modules.

4. CYNAERA Institute. (2025). SymCas™: Predictive Symptom Sequencing for Chronic Illness Flares. CYNAERA Systems Library.

5. CYNAERA Institute. (2025). PULSE™: Underreporting Detection in Public Health Data. CYNAERA White Paper Series.